Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Vectura Group PLC Add to portfolio

FTAL:VEC, May 29, 11:11 UTC

Latest FTAL:VEC News

Filter your feed

Apply Filter

Wednesday, November 27


News

Hikma and Vectura make new application for GSK knock-off

VEC GSK +1 more VEC GSK HIK

Hikma and Vectura make new application for GSK knock-off. The generics giant and the inhaled medicines specialist have developed VR315US, a knock-off version of GlaxoSmithKline PLC’s (LON:GSK) top-selling asthma treatment, Advair Diskus, which generated sales of around US$1bn last year. The US Food and Drug Administration (FDA) last year rejected a previous application, requesting further data that the companies said has been added to the new submission after the completion of a clinical endpoint study. The drug will compete with GSK’s Advair as well as Wixela Inhub, another generic version launched in February 2019 by Dutch firm Mylan NV (NASDAQ:MYL) and UK partner Consort Medical PLC (LON:CSRT).

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Sunday, November 10


News

Vectura Group (LON:VEC) Given Buy Rating at Citigroup

VEC

Citigroup reiterated their buy rating on shares of Vectura Group (LON:VEC) in a research report report published on Thursday, ThisIsMoney.Co.Uk reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Vectura Group has a consensus rating of Buy and a consensus price target of GBX 133.50 ($1.74). Vectura Group has a one year low of GBX 0.91 ($0.01) and a one year high of GBX 97.66 ($1.28).

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Saturday, November 09


News

Vectura Group (OTCMKTS:VEGPF) Stock Price Up 7.9% – Mitchell Messenger

VEC

Vectura Group PLC (OTCMKTS:VEGPF)’s share price rose 7.9% during trading on Thursday . The stock traded as high as $1.09 and last traded at $1.09, approximately 288 shares traded hands during mid-day trading. Zacks Investment Research lowered shares of Vectura Group from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Saturday, November 02


News

Vectura Group (LON:VEC) Given Hold Rating at Peel Hunt

VEC

Peel Hunt reissued their hold rating on shares of Vectura Group (LON:VEC) in a report published on Tuesday morning, ThisIsMoney.Co.Uk reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Vectura Group stock traded up GBX 0.10 ($0.00) during mid-day trading on Tuesday, hitting GBX 88.30 ($1.15). Vectura Group has a fifty-two week low of GBX 0.91 ($0.01) and a fifty-two week high of GBX 97.66 ($1.28).

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, October 29


News

Vectura Group appoints New Chief Executive Officer

VEC

Chippenham, UK – 29 October 2019: Vectura Group plc (VEC.L) ("Vectura", the "Group", or the "Company"), is pleased to announce the appointment of Will Downie as CEO and Executive Director of the Company with effect from 7th November 2019. He has a deep understanding of the development and advanced drug delivery market and has amassed significant experience in driving sustained long-term results, as well as building performance-focused organisations and meeting customer needs on a global scale. Prior to Catalent, Will held positions as Vice President & General Manager, Global Molecular Imaging at GE Healthcare, Vice President Sales EMEA at Amersham Health and Director of Business Development and Commercial Operations at Quintiles Innovex UK Limited. Will Downie commented: "I am delighted to have accepted the role of CEO of Vectura and to have the opportunity to expand and build on its reputation as an inhalation device and formulation specialist. I am looking forward to driving the new business strategy and ensuring the Company achieves its long-term goal of becoming a world class CDMO organisation in the inhalation space."

Read Full Details

Topics:
  • Business
  • Financial

Thursday, October 10


News

Is It Time To Scroll Stock?: Vectura Group Plc (LSE:VEC)

VEC

The level of trading activity in a stock is often a good proxy for the level of interest and enthusiasm for the name within the investment community. Active investor focuses on important indicators those changes daily in trading session that includes where the Vectura Group Plc (LSE:VEC) stock price change moved UP, DOWN or UNCHNAGE? What is market trading price of stock? How much shares are traded? What is market worth of stock? What technical say? How much stock is volatile? Having a look at the daily price change trend and size of price movement it is noted that VEC spotted a performance behavior with drift of -0.82% or GBX -0.7points. The stock has a beta of 0.999488 compared to a beta of 1 for the market, which implies that the stock’s price movements are less extreme than the market as a whole.

Read Full Details

Topics:
  • Business
  • Financial

Friday, October 04


News

Vectura, Sandoz gets favourable ruling in inhaler packaging case against GSK

VEC GSK

Vectura, Sandoz gets favourable ruling in inhaler packaging case against GSK. (Reuters) - Vectura Group <VEC.L> said on Friday a British court had ruled in its and partner Sandoz's <NOVN.S> favour over the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline <GSK.L>. Vectura said the court dismissed all GSK claims related to the packaging of AirFluSal Forspiro, which it developed in partnership with Swiss drugmaker Novartis-owned Sandoz as a branded copycat of GSK's asthma inhaler, Seretide Accuhaler. Sandoz launched AirFluSal Forspiro in late 2015, following which GSK filed a legal claim that Sandoz had used shades of purple similar to Seretide's packaging to pass off AirFluSal Forspiro as being related to GSK's product. Forspiro is a dry powder inhaler developed by Vectura andlicensed to Sandoz for use with the AirFluSal product.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Science

Thursday, September 19


News

Vectura Group PLC (LON:VEC) Receives Average Recommendation of “Buy” from Brokerages – TechNewsObserver

VEC

Vectura Group PLC (LON:VEC) has been assigned a consensus recommendation of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is GBX 116 ($1.52). Morgan Stanley restated a “buy” rating and set a GBX 160 ($2.09) price objective on shares of Vectura Group in a research note on Friday, May 24th. Vectura Group has a 52-week low of GBX 65.85 ($0.86) and a 52-week high of GBX 90.15 ($1.18).

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, September 13


News

Vectura provides update on GSK Litigation

VEC GSK

Paul Fry, Vectura’s Chief Financial Officer and Interim Chief Executive Officer of Vectura, said: “The judge’s post-motions ruling further validates Vectura’s original decision to pursue this action with GSK. We will always take action to protect and defend our intellectual property and we will provide further updates on this matter in due course.”. This interest will accrue on the damages awarded by the jury, supplemental damages and prejudgment interest, and will accrue going forward until Vectura is compensated by GSK. Judge Andrews denied the following motions: GSK’s motion for judgment of non-infringement, GSK’s motion for judgment of obviousness, GSK’s motion for a finding of no wilful infringement, GSK’s motion for a new trial, GSK’s motion for a reduction in the amount of damages awarded by the jury, Vectura’s motion for enhanced damages, and Vectura’s motion for attorney’s fees.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, September 11


News

Vectura Group (LON:VEC) Rating Reiterated by Peel Hunt – Slater Sentinel

VEC

Vectura Group (LON:VEC)‘s stock had its “hold” rating reiterated by equities research analysts at Peel Hunt in a research report issued on Monday, ThisIsMoney.Co.Uk reports. Finally, Morgan Stanley reiterated a “buy” rating and set a GBX 160 ($2.09) target price on shares of Vectura Group in a research report on Friday, May 24th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Vectura Group stock opened at GBX 79.70 ($1.04) on Monday.

Read Full Details

Topics:
  • Business
  • Health
  • Financial